ClinicalTrials.gg
CompletedNCT05041803Updated Nov 21, 2025Results posted

European Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata

A Phase 3 interventional study of CTP-543 in Alopecia Areata, sponsored by Sun Pharmaceutical Industries, Inc.. Completed at 39 sites in 5 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-11-21.

Sponsored by Sun Pharmaceutical Industries, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
407
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing deuruxolitinib in Alopecia Areata — 2 open to participants now, 3 under way, 3 of them phase 3. Deuruxolitinib · Alopecia Areata.

Enrollment
4th of 10
407 · median 336
Started
2021
with 2 others
Phase 3
5 of 10
2 open now
Registered
8th of 10
by date
Lead sponsor
3 of 10
Sun Pharmaceutical Industries, Inc.

Among the 10 studies testing deuruxolitinib in Alopecia Areata, this one is the 4th largest by enrollment, is one of 3 that started in 2021, is one of 5 in phase 3, and was the 8th registered.

Alopecia Areata

220 studies on the registry are indexed under Alopecia Areata; 61 are open to participants now.

Browse Alopecia Areata studies →

Open to participants now

2 of the 10 studies testing deuruxolitinib in Alopecia Areata are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About deuruxolitinib

Deuruxolitinib: first FDA approval 2024 (LEQSELVI). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 41 Alopecia Areata studies recruiting now, 16 (39%) set no upper age limit and 21 (51%) stop at 75 or younger; 20 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing deuruxolitinib in Alopecia Areata, or all of them as a file.
02

Study summary

The overall objectives of the study are to evaluate long-term safety of CTP-543 and to assess long-term effects of CTP-543 on treating hair loss in adult patients with chronic, severe alopecia areata. Patients from European sites who previously completed a qualifying CTP-543 clinical trial may participate in this study.

03

Conditions studied

  • Alopecia Areata

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have completed 24 weeks of treatment in a previous qualifying CTP-543 clinical trial

Exclusion criteria

Exclusion Criteria:

  • Active scalp inflammation, psoriasis, or seborrheic dermatitis requiring topical treatment to the scalp, significant trauma to the scalp, or untreated actinic keratosis
  • Females who are nursing, pregnant, or planning to become pregnant while in the study, and for 30 days after last dose of study medication
  • Donation of blood at any point throughout the study and for 30 days after last dose of study medication
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
407 participants (actual)

Study arms

  • Experimental
    CTP-543

    Patients who previously completed a qualifying CTP-543 clinical trial

    Drug: CTP-543

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events as a Measure of Safety

    Time frame: 108 weeks

  2. Relative Change From Pre-zero Baseline in Total Severity of Alopecia Tool (SALT) Scores at Week 108

    SALT is a quantitative assessment of scalp hair loss with scores ranging from 0 (no scalp hair loss) to 100 (complete scalp hair loss). This outcome measures the relative Change from Pre-zero Baseline in Total SALT Scores. Relative change from baseline was defined as 100\*(post-baseline value - baseline)/baseline.

    Time frame: 108 weeks

07

Results

Posted Nov 21, 2025

Participant flow

Participant flow — Overall Study
MilestoneCTP-543 8 mg BIDCTP-543 12 mg BID
Started255152
Completed201127
Not completed5425

Outcome measures

PrimaryNumber of Participants With Adverse Events as a Measure of Safety
Time frame:
108 weeks
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events as a Measure of Safety
ParticipantsCTP-543 8 mg BIDCTP-543 12 mg BID
Number of Participants With Adverse Events as a Measure of Safety308224
PrimaryRelative Change From Pre-zero Baseline in Total Severity of Alopecia Tool (SALT) Scores at Week 108

SALT is a quantitative assessment of scalp hair loss with scores ranging from 0 (no scalp hair loss) to 100 (complete scalp hair loss). This outcome measures the relative Change from Pre-zero Baseline in Total SALT Scores. Relative change from baseline was defined as 100\*(post-baseline value - baseline)/baseline.

Time frame:
108 weeks
Reported as:
Mean · Percentage change
Relative Change From Pre-zero Baseline in Total Severity of Alopecia Tool (SALT) Scores at Week 108
Percentage changeCTP-543 8 mg BIDCTP-543 8 mg BID to CTP-543 12 mg BIDCTP-543 12 mg BID to CTP-543 8 mg BID
Relative Change From Pre-zero Baseline in Total Severity of Alopecia Tool (SALT) Scores at Week 108-96.38 ± 8.790-88.57 ± 18.715-90.25 ± 18.860

Adverse events

Collected over 108 Weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CTP-543 8 mg BID0/367 (0%)16/367 (4.4%)176/367 (48%)
CTP-543 12 mg BID0/273 (0%)5/273 (1.8%)127/273 (46.5%)
Most frequent serious events
Showing 10 of 23
Most frequent serious events
EventCTP-543 8 mg BIDCTP-543 12 mg BID
OsteoarthritisMusculoskeletal and connective tissue disorders2/3670/273
Bartholin's abscessInfections and infestations0/3671/273
Humerus fractureInjury, poisoning and procedural complications0/3671/273
Synovial cystMusculoskeletal and connective tissue disorders0/3671/273
Abdominal painGastrointestinal disorders1/3671/273
Tongue neoplasm malignant stage unspecifiedNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/3671/273
Bartholin's cystReproductive system and breast disorders0/3671/273
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/3671/273
Hepatitis EInfections and infestations1/3670/273
Infectious mononucleosisInfections and infestations1/3670/273
Most frequent other events
Showing 10 of 11
Most frequent other events
EventCTP-543 8 mg BIDCTP-543 12 mg BID
Asymptomatic COVID-19Infections and infestations83/36758/273
COVID-19Infections and infestations78/36744/273
NasopharyngitisInfections and infestations76/36748/273
Blood creatine phosphokinase increasedInvestigations42/36724/273
HypercholesterolaemiaMetabolism and nutrition disorders41/36729/273
ThrombocytosisBlood and lymphatic system disorders20/36726/273
Upper respiratory tract infectionInfections and infestations30/36714/273
HeadacheNervous system disorders23/3679/273
AnaemiaBlood and lymphatic system disorders13/36714/273
Weight increasedInvestigations14/36714/273

Baseline characteristics

Age, Continuous
Age, Continuous(years)CTP-543 8 mg BIDCTP-543 12 mg BIDTotal
Mean38.9 ± 12.4138.2 ± 12.8638.7 ± 12.57
Sex: Female, Male
Sex: Female, Male(Participants)CTP-543 8 mg BIDCTP-543 12 mg BIDTotal
Female18189270
Male7463137
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)CTP-543 8 mg BIDCTP-543 12 mg BIDTotal
Hispanic or Latino7512
Not Hispanic or Latino186117303
Unknown or Not Reported623092
Race (NIH/OMB)
Race (NIH/OMB)(Participants)CTP-543 8 mg BIDCTP-543 12 mg BIDTotal
American Indian or Alaska Native000
Asian011
Native Hawaiian or Other Pacific Islander000
Black or African American000
White193121314
More than one race000
Unknown or Not Reported623092
08

Study locations

39 sites
  • Service de Dermatologie CHRU de Brest - Hopital Morvan
    Brest, Finistere 29609, France
  • Service de Dermatologie Centre Hospitalier Universitaire de Nice - Hopital Archet 2
    Nice, Provence-Alpes-Côte d'Azur Region 06202, France
  • CHU de Bordeaux, Hopital Saint-Andre
    Bordeaux, 33000, France
  • Hopital Saint-Louis - GH De La Rochelle-Re-Aunis
    La Rochelle, 17019, France
  • Hôpital La Timone-Dermatologie
    Marseille, 13385, France
  • Hopital de l'Hotel Dieu - CHU de Nantes
    Nantes, 22093, France
  • Hôpital Saint Louis, Centre de Santé Sabouraud
    Paris, 75010, France
  • Centre Hospitalier Universitaire de Toulouse - Hopital Larrey
    Toulouse, 31059, France
  • Universitätsklinikum Tübingen Universitäts-Hautklinik
    Tübingen, Baden-Wüttermberg 72076, Germany
  • Universitätsklinikum Erlangen, Hautklinik
    Erlangen, Bavaria 91054, Germany
  • Klinikum Rechts der Isar, Technische Universität München, Hautklinik
    München, Bavaria 80802, Germany
  • Klinik für Dermatologie, Venerologie und Allergologie
    Frankfurt am Main, Hesse 60590, Germany
  • Fachklinik Bad Bentheim
    Bad Bentheim, Lower Saxony 48455, Germany
  • Klinik für Dermatologie und Venerologie, Zentrale Studienkoordination für innovative Dermatologie (ZiD)
    Münster, North Rhine-Westphalia 48149, Germany
  • Clinical Research Center for Hair and Skin Science, Dept of Dermatology, Charité Universitätsmedizin Berlin
    Berlin, 10117, Germany
  • Pecsi Tudomanyegyetem Klinikai Kozpont, Bor-, Nemikortani es Onkodermatologiai Klinika
    Pécs, Baranya 7632, Hungary
  • SZTE AOK Szent-Gyorgyi Albert Klinikai Kozpont, Borgyogyaszati es Allergologiai Klinika
    Szeged, Csongrad-Csanad County 6720, Hungary
  • Semmelweis Egyetem AOK, Bor-, Nemikortani es Boronkologiai Klinika
    Budapest, Pest County 1085, Hungary
  • Twoja Przychodnia Centrum Medyczne Nowa Sol
    Nowa Sól, Lubusz Voivodeship 67-100, Poland
  • ETG Siedlce
    Siedlce, Masovian Voivodeship 08-110, Poland
  • ETG Skierniewice
    Skierniewice, Masovian Voivodeship 96-100, Poland
  • RCMed Oddzial w Sochaczewie
    Sochaczew, Masovian Voivodeship 96-500, Poland
  • OT.CO Clinic Klinika Osipowicz & Turkowski sp. z o.o
    Warsaw, Masovian Voivodeship 00-716, Poland
  • Carpe Diem Centrum Medycyny Estetycznej
    Warsaw, Masovian Voivodeship 02-661, Poland
  • ETG Warszawa
    Warsaw, Masovian Voivodeship 02-793, Poland
  • NZOZ Specjalistyczny Osrodek Dermatologiczny DERMAL
    Bialystok, 15-453, Poland
  • Vita Longa Sp.Zo.O
    Katowice, 40-748, Poland
  • Specjalistyczny Gabinet Dermatologiczny s.c.
    Krakow, 30-002, Poland
  • Twoja Przychodnia - Szczecinskie Centrum Medyczne
    Szczecin, 71-500, Poland
  • My Clinic
    Warsaw, 00-144, Poland
  • Royalderm Agnieszka Nawrocka
    Warsaw, 02-962, Poland
  • WroMedica I. Bielicka, A. Strazalkowska s.c.
    Wroclaw, 51-685, Poland
  • Hospital Clínic de Barcelona
    Barcelona, Barcelona/Cataluña 08036, Spain
  • Hospital del Mar
    Barcelona, 08003, Spain
  • Hospital de La Santa Creu i Sant Pau
    Barcelona, 08041, Spain
  • Hospital Universitario Reina Sofía
    Córdoba, 14004, Spain
  • Hospital Universitario Ramón y Cajal
    Madrid, 28034, Spain
  • Hospital 12 de Octubre
    Madrid, 28041, Spain
  • Hospital Universitario La Paz
    Madrid, 28046, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2021 to primary completion in Jul 2024, 32 months.

Results were first posted in Nov 2025, 1 year 4 months after primary completion.

Of 20 phase 3 interventional studies under Alopecia Areata, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 46. This study's 32 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 3, 2021
First posted
Sep 13, 2021
StartActual
Oct 19, 2021
Primary completionActual
Jul 18, 2024
CompletionActual
Jul 18, 2024
Results first posted
Nov 21, 2025
Last update
Nov 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05041803
Responsible party
Sponsor
First posted
Sep 13, 2021
Start date
Oct 19, 2021
Primary completion
Jul 18, 2024
Completion
Jul 18, 2024
Results posted
Nov 21, 2025
Last update
Nov 21, 2025

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Deuruxolitinib

Start the discussion